Clinical virology of cytomegalovirus infection following hematopoietic transplantation

Future Virology

Volumn 5, Issue 1, 2010, Pages 111-124

  Solano, Carlos ^a,b   Navarro, David ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Allo SCT; Allogeneic stem cell transplantation; Antigenemia assay; CMV; CMV pathogenicity; CMV resistance; Cytomegalovirus; Immunological monitoring; Real time PCR

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CD27 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIGEN PP65; DNA POLYMERASE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; HLA ANTIGEN; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATURAL KILLER CELL RECEPTOR; PHOSPHOTRANSFERASE; RAPAMYCIN; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR; VIRULENCE FACTOR; VIRUS DNA;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRIFUGATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DNA DETERMINATION; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENOTYPE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; INFECTION RISK; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; NEUTROPENIA; PATHOGENESIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS CULTURE; VIRUS LOAD; VIRUS VIRULENCE;

CYTOMEGALOVIRUS;

EID: 74049134360     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.64     Document Type: Review

References (98)

1. Hebart H, Einsele H: Clinical aspects of CMV infection after stem cell transplantation. Hum. Immunol. 65, 432-436 (2004).
2. Boeckh M, Ljungman P: Cytomegalovirus infection after bone marrow transplantation. In: Transplant Infections. Paya C (Ed.). Lippincot-Raven Philadelphia, PA, USA, 215-227 (1998).
3. Boeckh M, Nichols WG, Papanicolau G, Rubin R, Wingard JR, Zaia J: Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9, 543-558 (2003). ■ Comprehensive review dealing with several critical issues of cytomegalovirus (CMV) infection in the allogeneic stem cell transplantation (Allo-SCT) setting.
4. Ljungman P: CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 42, S70-S72 (2008).
5. Ozdemir E, Saliba RM, Champlin RE et al.: Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 40, 125-136 (2007).
6. Zhou W, Longmate J, Lacey SF et al.: Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113, 6465-6476 (2009).
7. Ljungman P, Perez-Bercoff L, Jonsson J et al.: Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91, 78-83 (2006). ■ Large study assessing risk factors for the occurrence of CMV disease.
8. Boeckh M, Nichols WG: The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103, 2003-2008 (2004).
9. Junghanss C, Boeckh M, Carter RA et al.: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99, 1978-1985 (2002).
10. Nakamae H, Kirby KA, Sandmaier BM et al.: Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15, 694-703 (2009).
11. Ljungman P, de la Camara R, Cordonnier C et al.: Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 42, 227-240 (2008). ■ Consensus document for the management of CMV infection in Allo-SCT recipients.
12. Ljungman P, Griffiths P, Paya C: Definitions of HCMV infection and disease in transplant recipients. Clin. infect. Dis. 34, 1094-1097 (2002). ■ Consensus clinical and laboratory criteria for the diagnosis of CMV infection and disease.
13. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83, 1971-1979 (1994).
14. Boeckh M, Leisenring W, Riddell SR: Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplant recipients: importance of viral load and T-cell immunity. Blood 101, 407-414 (2003). ■ Large study defining risk factors for late CMV disease.
15. Boeckh M, Nichols GW: Immunosuppressive effects of α-herpesviruses. Herpes 10, 12-16 (2003).
16. Wang LR, Dong LJ, Zhang MJ, Lu DP: Correlations of human herpesvirus 6B and CMV infection with acute GvHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 42, 673-677 (2008).
17. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J. Infect. Dis. 185, 273-282 (2002). ■ Key study demonstrating the association between CMV infection and increased risk of microbial superinfection (indirect effect).
18. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD: Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355, 2032-2036 (2000).
19. Stachel D, Kirby K, Corey L, Boeckh M: Viral load as predictor for transplant-related mortality in the era of pre-emptive therapy. Bone Marrow Transplant. 41, S46 (2008).
20. van der Bij W, Torensma R, van Son WJ et al.: Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J. Med. Virol. 25, 179-188 (1988). ■ Development of the pp65 antigenemia assay.
21. van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH: Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J. Clin. Microbiol. 26, 2531-2535 (1988).
22. Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11, 533-544 (1998).
23. Gerna G, Percivalle E, Torsellini M, Revello MG: Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J. Clin. Microbiol. 36, 3585-3589 (1998).
24. Gimeno C, Solano C, Latorre JC et al.: Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46, 3311-3318 (2008).
25. Gerna G, Lilleri D, Zecca M et al.: Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 90, 526-533 (2005).
26. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. doi: 10.1038/bmt.2009.172 (2009) (Epub ahead of print).
27. Solano C, Muñoz I, Gutiérrez A et al.: Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J. Clin. Microbiol. 39, 3938-3941 (2001).
28. Jang EY, Park SY, Lee EJ et al.: Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin. infect. Dis. 48, 121-124 (2009).
29. Espy MJ, Uhl JR, Sloan M et al.: Real-time PCR in clinical microbiology: Applications for routine laboratory testing. Clin. Microbiol. Rev. 19, 165-256 (2006). ■ Comprehensive review on the use of real-time PCR technology in the diagnosis of microbial infections.
30. Boeckh M, Huang M, Ferrenberg J et al.: Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J. Clin. Microbiol. 42, 142-1148 (2004).
31. Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH: Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J. Clin. Microbiol. 39, 4362-4369 (2001).
32. Harrington SM, Buller RS, Storch GA et al.: The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic stem cell transplant patients. Bone Marrow Transplant. 39, 237-238 (2007).
33. Herrman B, Larsson VC, Rubin CJ et al.: Comparison of a duplex real-time PCR assay and the COBAS Amplicor CMV monitor test for detection of cytomegalovirus. J. Clin. Microbiol. 42, 1909-1914 (2004).
34. Hong KM, Najjar H, Hawley M, Press RD: Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients. Clin. Chem. 50, 846-856 (2004).
35. Kalpoe JS, Kroes ACM, de Jong MD et al.: Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by ana lysis of correlation to antigen detection. J. Clin. Microbiol. 42,1498-1504 (2004).
36. Leurez-Ville M, Ouachée M, Delarue R et al.: Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J. Clin. Microbiol. 41, 2040-2046 (2003).
37. Limaye AP, Huang ML, Leisenring W, Stensland L, Corey L, Boeckh M: Cytomegalovirus (CMV) DNA in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J. Infect. Dis. 183, 377-382 (2001).
38. Machida U, Kami M, Fukui T et al.: Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J. Clin. Microbiol. 38, 2536-2542 (2000).
39. Mori T, Okamoto S, Watanabe R et al.: Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic stem cell transplantation. Bone Marrow Transplant. 29, 777-782 (2002).
40. Nitsche A, Steuer N, Schmidt CA et al.: Detection of cytomegalovirus DNA by real-time quantitative PCR. J. Clin. Microbiol. 38, 2734-2737 (2000).
41. Pumannova M, Roubalova K, Vitek A, Sajdova J: Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation. Diagn. Microbiol. Infect. Dis. 54, 115-120 (2006).
42. Ruell J, Barnes C, Mutton K et al.: Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 40, 55-61 (2007).
43. Schaade L, Kockelkorn P, Ritter K, Kleines M: Detection of cytomegalovirus DNA in human specimens by LightCycler PCR. J. Clin. Microbiol. 38, 4006-4009 (2000).
44. Tanaka Y, Kanda Y, Kami M et al.: Monitoring cytomegalovirus infection by antigenemia assay and two distinct real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 30, 315-319 (2002).
45. Tanaka N, Kimura H, Lida K et al.: Quantitative ana lysis of cytomegalovirus load using a real-time PCR assay. J. Med. Virol. 60, 455-462 (2000).
46. Verkruyse LA, Storch GA, Devine SM, DiPersio JF, Vij R: Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ≥10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 37, 51-56 (2006).
47. Yakushiji K, Gondo H, Kamenazi K et al.: Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant. 29, 599-606 (2002).
48. Yun Z, Lewensohn-Fuchs I, Ljungman P, Ringholm L, Jonsson J, Albert J: A real-time TaqMan PCR for routine quantification of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J. Virol. Methods 110, 73-79 (2003).
49. Pang XL, Fox JD, Fenton JM et al.: Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9, 258-268 (2009).
50. Caliendo AM, Ingersoll J, Fox-Canale A et al.: Evaluation of real-time PCR laboratory-developed test using analyte-specific reagents for cytomegalovirus quantification. J. Clin. Microbiol. 45, 1723-1727 (2007).
51. Gouarin S, Vabret A, Scieux C et al.: Multicentric evaluation of a new commercial cytomegalovirus real-time PCR quantification assay. J. Virol. Methods 146, 147-154 (2007).
52. Hanson KE, Reller LB, Kurtzberg J, HorwitzM, Long G, Alexander BD: Comparison of the Digene Hybrid capture system cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analyte-specific reagent, and Qiagen RealArt CMV LightCycler PCR reagent test using AcroMetrix OptiQuant CMV DNA quantification panels and specimens from allogeneic-stem-cell transplant recipients. J. Clin. Microbiol. 45, 1972-1973 (2007).
53. Yerly S, Perrin L, van Delden C et al.: Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J. Clin. Virol. 38, 298-303 (2007).
54. Allice T, Cerutti F, Pittaluga F et al.: Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment. J. Virol. Methods 148, 9-16 (2008).
55. Abbate I, Finnstrom N, Zaniratti S et al.: Evaluation of an automated extraction system in combination with Affigene® CMV Trender for CMV DNA quantitative determination: comparison with nested PCR and pp65 antigen test. J. Virol. Methods 151, 61-65 (2008).
56. Michelin BD, Hadzisejdic I, Bozic M et al.: Detection of cytomegalovirus (CMV) DNA in EDTA whole-blood samples: evaluation of the quantitative artus CMV LightCycler PCR kit in conjunction with automated sample preparation. J. Clin. Microbiol. 46, 1241-1245 (2008).
57. Vincent E, Gu Z, Morgenstern M et al.: Detection of cytomegalovirus in whole blood using three different real-time PCR chemistries. J. Mol. Diagn. 11, 54-59 (2009).
58. Wolff DJ, LaMarche Heaney D, Neuwald PD, Stellrecht KA, Press RD: Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization. J. Mol. Diagn. 11, 87-91 (2009).
59. Garrigue I, Doussau A, Asselineau J et al.: Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J. Clin. Microbiol. 46, 493-498 (2008).
60. Zaia J: Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin. infect. Dis. 35, 999-1004 (2002).
61. Meijer E, Boland GJ, Verdonck LF: Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin. Microbiol. Rev. 16, 647-657(2003).
62. Boeckh M, Ljungman P: How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113, 5711-5719 (2009). ■■ Practical approach to the management of CMV infection in the Allo-SCT setting.
63. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M: Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 15, 1-12 (2008).
64. Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P: Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 38, 687-692 (2006).
65. Gerna G, Lilleri D, Caldera D et al.: Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 41, 873-879 (2008). ■■ Prospective randomized study stablishing a clinically safe whole-blood CMV DNAemia threshold for triggering the initiation of preemptive therapy.
66. Lilleri D, Baldanti F, Gatti M et al.: Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J. Med. Virol. 73, 412-418 (2004).
67. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P: Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 40, 865-869 (2007). ■■ Pioneer study proving the clinical utility and safeness of an intervention therapeutic strategy based on routine monitoring of CMV-specific immunity.
68. Ljungman P: Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J. Clin. Virol. 35, 493-495 (2006).
69. Baldanti F, Lilleri D, Gerna G: Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237-241 (2008).
70. Quinnan GV, Kirmani N, Rook AH et al.: Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307, 7-13 (1982).
71. Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78, 1373-1380 (1991).
72. + cytotoxic T cells against CMV infection.
73. + T cells in protection against CMV infection.
74. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E: Human NK cells can control CMV infection in the absence of T cells. Blood 112, 914-915 (2008).
75. Muñoz I, Gutiérrez A, Gimeno C et al.: Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J. Med. Virol. 65, 77-84 (2001).
76. Crough T, Khanna R: Immunobiology of human cytomegalovirus: from bench to benchside. Clin. Microbiol. Rev. 22, 76-98 (2009). ■ Discusses several interesting biological aspects of CMV infection.
77. Gutiérrez A, Muñoz I, Solano C et al.: Immunophenotyping may provide useful information for the clinical management of CMV infection. J. Med. Virol. 70, 399-403 (2003).
78. Cwynarski K, Ainsworth J, Cobbold M et al.: Direct visualization of cytomegalovirusspecific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97, 1232-1240 (2001). ■■ Pioneer study on the use of new immunological assays in assessing the CMV specific T-cell response in Allo-SCT recipients.
79. Aubert G, Hassan-Walker AF, Madrigal JA et al.: Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J. Infect. Dis. 184, 955-963 (2001).
80. Hebart H, Daginik S, Stevanovic S et al.: Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99, 3830-3837 (2002).
81. Ohnishi M, Sakurai T, Heike Y et al.: Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-γ- enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br. J. Haematol. 131, 472-479 (2005).
82. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93, 248-256 (2008).
83. + T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 93, 1434-1436 (2008). ■ Definition of peripheral levels of functional CMV-specific T cells providing early protection against CMV DNAemia after Allo-SCT.
84. Moins-Teisserenc H, Busson M, Scieux C et al.: Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J. Infect. Dis. 198, 818-826 (2008).
85. Chemaly RF, Yen-Lieberman B, Chapman J et al.: Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am. J. Transplant. 5, 544-548 (2005).
86. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC: Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis. 190, 1076-1083 (2004).
87. Gerna G, Lilleri D, Rognoni V et al.: Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am. J. Transplant. 9, 1142-1150 (2009).
88. Gilbert C, Boivin G: Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49, 873-883 (2005). ■ Comprehensive review on biological and clinical aspects of CMV antiviral resistance.
89. Baldanti F, Lurain N, Gerna G: Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 65, 403-409 (2004).
90. Andrei G, De Clercq E, Snoeck R: Novel inhibitors of human CMV. Curr. Opin. Investig. Drugs 9, 132-134 (2008).
91. Cobbold M, Khan N, Pourgheysari B et al.: Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202, 379-386 (2005).
92. Einsele H, Kapp M, Grigoleit U: CMV-specific T cell therapy. Blood Cells Mol. Dis. 40, 71-75 (2008).
93. Tuthill M, Chen F, Paston S, de la Peña H, Rusakiewicz S, Madrigal A: The prevention and treatment of cytomegalovirus infection in hematopoietic stem cell transplantation. Cancer Immunol. Immunother. 58, 1481-1488 (2009).
94. Chou S: UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18, 233-246 (2008).
95. Pignatelli S, Dal Monte P, Rossini G, Landini MP: Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev. Med. Virol. 14, 383-410 (2004). ■ Discusses CMV genetic polimorphisms and their potential role in CMV virulence.
96. Cicin-Sain L, Podlech J, Messerle M, Reddehase MJ, Koszinowski UH: Frequent coinfection of cells explains functional in vivo complementation between cytomegalovirus variants in the multiply infected host. J. Virol. 79, 9492-9502 (2005).
97. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G: Mixed cytomegalovirus glycoprotein B genotypes in immunocopromised patients. Clin. Infect. Dis. 39, 155-161 (2004).
98. Humar A, Kumar D, Gilbert C, Boivin G: Cytomegalovirus (CMV)-glycoprotein B genotypes and response to antiviral therapy in solid-organ transplant recipients with CMV disease. J. Infect. Dis. 188, 581-584 (2003).